Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

PURPOSE: Patients with advanced GIST following standard imatinib and sunitinib often have good performance status and need additional therapy. This study tested nilotinib, a second-generation tyrosine kinase inhibitor, in patients with advanced GIST refractory to standard therapies. METHODS: This si...

Descripción completa

Detalles Bibliográficos
Autores principales: Cauchi, C., Somaiah, N., Engstrom, P. F., Litwin, S., Lopez, M., Lee, J., Davey, M., Bove, B., von Mehren, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313017/
https://www.ncbi.nlm.nih.gov/pubmed/22119758
http://dx.doi.org/10.1007/s00280-011-1785-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313017/
https://www.ncbi.nlm.nih.gov/pubmed/22119758
http://dx.doi.org/10.1007/s00280-011-1785-7

Ejemplares similares